Answers are grounded in this paper and cite their sources.
Carbapenems are the last line of defense against Gram-negative and Gram-positive bacteria that cause serious infections. Although they are resistant to most B-lactamases, the presence of carbapenem hydrolyzing enzymes known as carbapenemase has put their use as a last-resort antibiotic in jeopardy. These enzymes are produced most frequently by Enterobacteriaceae. True carbapenemase in Ambler molecular classes A, B, and D are frequently expressed by genes found in mobile genetic elements such plasmids, integrons, and transposons, which frequently contain many resistance determinants, further limiting treatment options. The worldwide development of carbapenem-resistant Gram-negative bacteria has resulted in a large number of nosocomial and community-acquired illnesses, which has become a major public health issue. In vitro evidence of the advantages of combination schemes against polymyxins is still available while polymyxins are still available.
No takes yet. Share an insight, caveat, or question.
Zenawork Sahile (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: